Autopsy report · NCT03773744

MG1-MAGEA3 With Ad-MAGEA3 and Pembrolizumab in Patients With Previously Treated Metastatic Melanoma or Cutaneous Squamous Cell Carcinoma

“insufficient suitable drug supply”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Phase 1

Sponsor

Turnstone Biologics, Corp.

Sponsor type

Industry

Conditions

Metastatic Melanoma; Squamous Cell Skin Carcinoma

Interventions

Ad-MAGEA3; MG1-MAGEA3; Pembrolizumab; Cyclophosphamide

Participants

0

Trials that died the same way

• Treatment of Cancer-Related Bone Pain by Using Bone-Targeted Radiation-Based Therapy (Sn-117m-DTPA) in Patients With Prostate Cancer That Has Spread to Bones
  “Insufficient drug supply” (96% match in meaning)
• Phase II Study of Fludarabine, Cytarabine (ARA-C) and Erwinase IV in Patients With Relapsed or Refractory Hematologic Malignancies
  “Problem with drug supply” (85% match in meaning)
• Sipuleucel-T, CT-011, and Cyclophosphamide for Advanced Prostate Cancer
  “Drug supply issues” (79% match in meaning)
• Effects of Antrodia Cinnamomea on the Hepatoma Patients After Transcatheter Hepatic Artery Chemoembolization
  “poor accrual and insufficient drug supply” (79% match in meaning)
• rhEndostatin Protein Involving Pediatric Patients With Cancer
  “Lack of drug supply” (76% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.